Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2025)
Adlai Nortye's (ANL) quarterly Total Non-Current Liabilities came in at $1.1 million in Q4 2025, up 165.18% year-on-year from $425000.0 in Q4 2024, and up 338.52% on a QoQ basis from $257000.0 in Q2 2025.
Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Adlai Nortye (ANL) has 4 years of Total Non-Current Liabilities data on file, last reported at $1.1 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 165.18% year-over-year to $1.1 million in Q4 2025; TTM through Dec 2025 was $1.1 million, a 165.18% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 165.18% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $1.1 million, up from $257000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ANL reached as high as $5.5 million in Q4 2023 and fell as low as $257000.0 in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $1.7 million across 4 years, with a median of $1.1 million in 2025.
- Across the five-year window, Total Non-Current Liabilities soared 342.48% in 2023 and tumbled 92.23% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $1.2 million in 2022, then surged by 342.48% to $5.5 million in 2023, then tumbled by 92.23% to $425000.0 in 2024, then jumped by 165.18% to $1.1 million in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.1 million in Q4 2025, $257000.0 in Q2 2025, and $425000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Jun 30, 2025 | 257,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 1.24 Mn |